MARKET

CELC

CELC

Celcuity Inc
NASDAQ
125.64
-5.42
-4.14%
After Hours: 125.00 -0.64 -0.51% 16:51 05/11 EDT
OPEN
131.26
PREV CLOSE
131.06
HIGH
132.70
LOW
124.56
VOLUME
938.50K
TURNOVER
--
52 WEEK HIGH
151.02
52 WEEK LOW
9.51
MARKET CAP
6.07B
P/E (TTM)
-33.1819
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CELC last week (0504-0508)?
Weekly Report · 12h ago
Analyst Reiterates Buy and $165 Price Target on Celcuity Following Encouraging VIKTORIA‑1 PIK3CA‑Mutant Data
TipRanks · 1d ago
Celcuity to report Q1 results, host webcast and conference call after market close
PUBT · 4d ago
Celcuity director David Dalvey reports disposal of 25,000 shares worth $3.52 million
PUBT · 5d ago
Celcuity director Richard E. Buller disposes of 9,000 common shares for $1,260,514
PUBT · 5d ago
Notable Monday Option Activity: CELC, XRX, FWRD
NASDAQ · 05/04 19:31
Stocks Fall Amid Rising Middle East Tensions
Barchart · 05/04 15:39
Celcuity Is Maintained at Market Outperform by Citizens
Dow Jones · 05/04 14:40
More
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

Webull offers Celcuity Inc stock information, including NASDAQ: CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELC stock methods without spending real money on the virtual paper trading platform.